The prevalence of somatic alterations in ATM (1%–16%), ATR (4%–10%), BRCA1 (6%), and BRCA2 (7%) support the evidence that members of the DNA repair cascade are drug candidates in HNSCC (Seiwert et al., 2015). The gene discussed is BRCA1; the disease is head and neck squamous cell carcinoma.